Clinical Trials · NCT02696148
A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 24
- Start date
- Mar 2016
- Locations
- 9 sites, United States
- Primary endpoint
- Number of treatment emergent adverse events